Venetoclax plus rituximab or obinutuzumab after allogeneic hematopoietic stem cell transplantation in chronic lymphocytic leukemia

Haematologica. 2019 May;104(5):e224-e226. doi: 10.3324/haematol.2018.212837. Epub 2019 Feb 21.

Affiliations

¹ University of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen-Bonn-Cologne-Duesseldorf, Germany.
² University of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen-Bonn-Cologne-Duesseldorf, Germany lukas.frenzel@uk-koeln.de.

No abstract available

Publication types

Case Reports
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Aged
Antibodies, Monoclonal, Humanized / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Bridged Bicyclo Compounds, Heterocyclic / administration & dosage
Female
Hematopoietic Stem Cell Transplantation / adverse effects*
Humans
Leukemia, Lymphocytic, Chronic, B-Cell / pathology
Leukemia, Lymphocytic, Chronic, B-Cell / therapy*
Male
Middle Aged
Neoplasm Recurrence, Local / drug therapy*
Neoplasm Recurrence, Local / etiology
Neoplasm Recurrence, Local / pathology
Prognosis
Rituximab / administration & dosage
Sulfonamides / administration & dosage

Substances

Antibodies, Monoclonal, Humanized
Bridged Bicyclo Compounds, Heterocyclic
Sulfonamides
Rituximab
venetoclax
obinutuzumab